Teduglutide for Enterocutaneous Fistula (ECF)

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The purpose of this study is to determine whether Teduglutide is safe and feasible to be given for the treatment of enterocutaneous fistula (ECF). The hypothesis is that the drug will be well tolerated and will improve the volume of daily ECF output as well as improve the functional quality of life.

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT01634971` - External Drainage Versus Internal Drainage of Pancreatic Duct With a Stent After Pancreaticoduodenectomy (EDIDPD)	Phase 2

NCT number	NCT02889393
Study type	Interventional
Source	University of Miami
Contact
Status	Completed
Phase	Phase 2
Start date	January 31, 2019
Completion date	July 15, 2021

Teduglutide for Enterocutaneous Fistula (ECF)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms